MA53669A - Compositions et procédés d'administration d'acides nucléiques - Google Patents

Compositions et procédés d'administration d'acides nucléiques

Info

Publication number
MA53669A
MA53669A MA053669A MA53669A MA53669A MA 53669 A MA53669 A MA 53669A MA 053669 A MA053669 A MA 053669A MA 53669 A MA53669 A MA 53669A MA 53669 A MA53669 A MA 53669A
Authority
MA
Morocco
Prior art keywords
compositions
methods
nucleic acid
acid delivery
delivery
Prior art date
Application number
MA053669A
Other languages
English (en)
Inventor
Aaron Larsen
Melissa Moore
Jennifer Nelson
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA53669A publication Critical patent/MA53669A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053669A 2018-09-20 2019-09-20 Compositions et procédés d'administration d'acides nucléiques MA53669A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734082P 2018-09-20 2018-09-20

Publications (1)

Publication Number Publication Date
MA53669A true MA53669A (fr) 2021-07-28

Family

ID=69887851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053669A MA53669A (fr) 2018-09-20 2019-09-20 Compositions et procédés d'administration d'acides nucléiques

Country Status (4)

Country Link
US (1) US20220298516A1 (fr)
EP (1) EP3852814A4 (fr)
MA (1) MA53669A (fr)
WO (1) WO2020061397A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008810A2 (pt) 2016-11-01 2019-07-16 Univ New York State Res Found micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
JP2024518546A (ja) * 2021-05-12 2024-05-01 ザ ブロード インスティテュート，インコーポレーテッド 修飾されたｍＲＮＡ、修飾された非コードＲＮＡ、およびその使用
WO2023141474A1 (fr) * 2022-01-18 2023-07-27 The Broad Institute, Inc. Arnm poly-queue et poly-coiffe et ses utilisations
WO2023250528A1 (fr) * 2022-06-24 2023-12-28 The Broad Institute, Inc. Compositions et procédés de préparation de molécules d'arn circulaires coiffées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105364A1 (fr) * 1993-09-01 1995-03-02 Eric T. Kool Oligonucleotides en forme de trefle, renfermant des domaines de fixation parallele et antiparallele
WO2013185067A1 (fr) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
CA2921556A1 (fr) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Compositions et procedes pour la modulation d'arn
WO2015196118A1 (fr) * 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Molécules d'acide nucléique différentes et utilisations

Also Published As

Publication number Publication date
EP3852814A1 (fr) 2021-07-28
WO2020061397A1 (fr) 2020-03-26
EP3852814A4 (fr) 2022-09-14
US20220298516A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MA53669A (fr) Compositions et procédés d'administration d'acides nucléiques
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA53919A (fr) Constructions d'acides nucléiques et procédés d'utilisation
GB2606038B (en) Compositions and methods for organ specific delivery of nucleic acids
GB2592504B (en) Compositions and methods for organ specific delivery of nucleic acids
MA51451A (fr) Compositions d'acides aminés et méthodes de traitement de maladies hépatiques
MA47824A (fr) Administration polyanionique d'acides nucléiques
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
IL283840A (en) Preparations for administering therapeutic substances and methods for their use and preparation
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d'acide
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
MA53239A (fr) Procédés d'administration de certains inhibiteurs de vmat2
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
EP3813853A4 (fr) Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
MA41951A (fr) Gènes insecticides et procédés d'utilisation
DK3727555T3 (da) Oral delivery of active drug substances
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA55893A (fr) Procédés d'administration de certains inhibiteurs de vmat2
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
MA46044A (fr) Compositions de nettoyage comprenant un acide aminé et leurs procédés d'utilisation
MA55452A (fr) Systèmes et procédés d'administration de médicament
IL262514A (en) Pharmaceutical preparations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies